Figure 6 : Pyrvinium pamoate inhibited growth of hepatocellular carcinoma in vitro and in vivo via targeting Wnt signaling.

From: Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

Figure 6

(a) Pyrvinium pamoate inhibited colony formation. One-way ANOVA followed by Dunnett's multiple comparisons test (****P=0.0001, 50 nM compared to cell medium). Data are shown as mean±s.d. of three independent biological replicates. (b) Pyrvinium pamoate disrupted Wnt signalling proteins in HepG2 and Huh7 cells. Cells were treated for 24 h with DMSO (indicated as C), 1.6 μM or 3.2 μM of pyrvinium pamoate. (c) Pyrvinium pamoate attenuates β-catenin-mediated TOPflash activity in HepG2 and Huh7 cells. TOPflash and the Renilla luciferase reporter (control) were co-transfected into respective cell lines, and incubated with pyrvinium pamoate at the indicated concentrations, followed by 4 h incubation with or without rhWNT3A (200 ng ml−1). Luciferase activity was normalized to Renilla concentrations in each sample and compared to vehicle control. For HepG2, one-way ANOVA followed by Dunnett's multiple comparisons test (***P=0.0001, 0.8 μM compared to 0 as control; ****P=0.0001, 1.6 μM, 3.2 μM compared to 0 as control). For Huh7, two-way ANOVA followed by Dunnett's multiple comparisons test (****P=0.0001, 0.8, 1.6 and 3.2 μM compared to 0 as control). Data are shown as mean±s.d. of three independent biological replicates. (d) Pyrvinium pamoate inhibited tumour growth in subcutaneous Huh7 xenografts in vivo (n=4 per group). Data are shown as mean±s.d. *P=0.035 (Student’s t-test). (e) Pyrvinium pamoate disrupted Wnt signalling proteins in subcutaneous Huh7 xenografts.